{"id":"896e1413-1918-5143-b708-dacc9cf7a843","stable_key":"d39c4b36-9a88-5f52-8e6b-93a248dc4bfc:hericenones-erinacines-human-enriched-mycelium","predicate":"is_associated_with","statement":"In a pilot 49-week double-blind trial, an erinacine-A-enriched mycelium product produced better selected cognitive and instrumental-activity outcomes than placebo; four participants stopped for gastrointestinal or skin symptoms.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"952acbaf-8cd2-5d41-8bf5-54e192a0ff43","mechanism_event_label":"In a pilot 49-week double-blind trial, an erinacine-A-enriched mycelium product produced better selected cognitive and instrumental-activity outcomes than placebo; four participants stopped for gastrointestinal or skin symptoms.","subject":{"id":"a0135c6c-200d-5795-b4e0-24dac53193db","slug":"erinacine-a-enriched-mycelial-extract","display_name":"Erinacine-A-containing Hericium mycelial extract","entity_type_key":"botanical"},"object":{"id":"4fb8ea65-b0d0-5cbd-886e-de1f7d2dbc64","slug":"mild-alzheimer-cognitive-and-functional-scores","display_name":"Cognitive and functional scores in mild Alzheimer's disease","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"952acbaf-8cd2-5d41-8bf5-54e192a0ff43","stable_key":"d39c4b36-9a88-5f52-8e6b-93a248dc4bfc:hericenones-erinacines-human-enriched-mycelium-event","event_type":"observed_relationship","label":"In a pilot 49-week double-blind trial, an erinacine-A-enriched mycelium product produced better selected cognitive and instrumental-activity outcomes than placebo; four participants stopped for gastrointestinal or skin symptoms.","description":"In a pilot 49-week double-blind trial, an erinacine-A-enriched mycelium product produced better selected cognitive and instrumental-activity outcomes than placebo; four participants stopped for gastrointestinal or skin symptoms.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"a0135c6c-200d-5795-b4e0-24dac53193db","slug":"erinacine-a-enriched-mycelial-extract","display_name":"Erinacine-A-containing Hericium mycelial extract","entity_type_key":"botanical"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"4fb8ea65-b0d0-5cbd-886e-de1f7d2dbc64","slug":"mild-alzheimer-cognitive-and-functional-scores","display_name":"Cognitive and functional scores in mild Alzheimer's disease","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"dose","value_text":"Three 350 mg mycelium capsules/day containing 5 mg/g erinacine A","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"duration","value_text":"49 weeks","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_access","value_text":"Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_scope","value_text":"literature_reviewed; model-specific source-derived curation","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Patients with mild Alzheimer's disease","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Small pilot product trial with industry affiliations; findings cannot be assigned to isolated erinacine A, hericenones, or all lion's-mane products.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Hericenones & Erinacines chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings.","comparator":null,"unit":null,"notes":"","entity":{"slug":"hericenones-erinacines","display_name":"Hericenones and erinacines","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"Patients with mild Alzheimer's disease","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"In a pilot 49-week double-blind trial, an erinacine-A-enriched mycelium product produced better selected cognitive and instrumental-activity outcomes than placebo; four participants stopped for gastrointestinal or skin symptoms.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Prevention of Early Alzheimer's Disease by Erinacine A-Enriched Hericium erinaceus Mycelia Pilot Double-Blind Placebo-Controlled Study. (2020). https://pubmed.ncbi.nlm.nih.gov/32581767/ DOI: 10.3389/fnagi.2020.00155","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"route","value_text":"Oral multi-constituent product","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue","value_text":"CASI, MMSE, IADL, imaging and biomarkers","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"bc9c55ee-8277-5c43-ae29-0fccccfc7a2f","evidence_kind":"source_excerpt","locator":"Lines 154-163","start_line":154,"end_line":163,"excerpt":"## hericenones-erinacines-human-enriched-mycelium\nIn a pilot 49-week double-blind trial, an erinacine-A-enriched mycelium product produced better selected cognitive and instrumental-activity outcomes than placebo; four participants stopped for gastrointestinal or skin symptoms.\nModel/species: Patients with mild Alzheimer's disease\nTissue/system: CASI, MMSE, IADL, imaging and biomarkers\nExposure: Three 350 mg mycelium capsules/day containing 5 mg/g erinacine A\nRoute: Oral multi-constituent product\nDuration: 49 weeks\nLimits: Small pilot product trial with industry affiliations; findings cannot be assigned to isolated erinacine A, hericenones, or all lion's-mane products.\nPrimary reference: Prevention of Early Alzheimer's Disease by Erinacine A-Enriched Hericium erinaceus Mycelia Pilot Double-Blind Placebo-Controlled Study. (2020). https://pubmed.ncbi.nlm.nih.gov/32581767/ DOI: 10.3389/fnagi.2020.00155\nAccess: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","model_system":"Patients with mild Alzheimer's disease","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Exact original curation span with primary citation; not a publisher quotation.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"aa7c09fd-ab4a-51ff-b463-d35547dc41ba","stable_key":"import-d39c4b36-9a88-5f52-8e6b-93a248dc4bfc","title":"Hericenones & Erinacines: mechanism of action and interactions (2026-09-20)","document_type":"imported_text","citation_label":"Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text.","file_path":"","sha256":"f1ff2966f222f5c463e8e509ec1b1642a0053cd38f121f3847cdd21855c46e85","revision_id":"d00076e0-da87-5100-92ed-0525190b25a1","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}